Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Jun
30
2022
PBMs Continue to Draw Federal Scrutiny: PBM Transparency Act of 2022 Mintz
Jun
30
2022
Final Revision to HBCD Risk Determination Finds HBCD, as a Whole Chemical Substance, Presents an Unreasonable Risk Bergeson & Campbell, P.C.
Jun
30
2022
How the Pharmacy Audit Appeals Process Works Oberheiden P.C.
Jun
30
2022
Now I Know My CBDs – Louisiana Court Favors Employee Terminated for Failing Marijuana Test Bradley Arant Boult Cummings LLP
Jun
29
2022
Time Is Not Always Money: Ninth Circuit Holds That Pre-Employment Drug Testing Is Not Compensable Under California Law Sheppard, Mullin, Richter & Hampton LLP
Jun
29
2022
California District Court Finds that EKRA Applies to Compensation Methodologies for Labs’ Employed Marketers Who Market to Physicians Sheppard, Mullin, Richter & Hampton LLP
Jun
29
2022
Georgia Court Finds Dietary Supplement Labeling Claim within FDA’s Jurisdiction Keller and Heckman LLP
Jun
29
2022
Congress Is Fully Funding EPA's Implementation of Its PFAS Road Map but Insisting on Knowing when EPA Will Get to Its PFAS Destinations Mintz
Jun
28
2022
Supreme Court’s Mens Rea Decision in Drug Case May Have Significant Implications for False Claims Act Cases Based on Anti-Kickback Violations Greenberg Traurig, LLP
Jun
28
2022
DC City Council Enacts Major New Workplace Protections for Marijuana Users ArentFox Schiff LLP
Jun
28
2022
Senate Committee Passes the FDA Safety and Landmark Advancements Act Keller and Heckman LLP
Jun
28
2022
EPA Announces New Chemical Engineering Initiative Intended to Increase Transparency and Reduce Rework Bergeson & Campbell, P.C.
Jun
27
2022
PFAS Regulations Could Open Floodgates to Prop 65 Enforcement – Assess & Manage Your Exposure Now Sheppard, Mullin, Richter & Hampton LLP
Jun
27
2022
Supreme Court Rules for Physicians in Blow to DOJ Sheppard, Mullin, Richter & Hampton LLP
Jun
27
2022
CMS Releases Cy 2023 End-Stage Renal Disease Prospective Payment System Proposed Rule McDermott Will & Emery
Jun
27
2022
Three Considerations for Health Care Providers After the Dobbs Decision Foley & Lardner LLP
Jun
27
2022
JANAAC Recognized as an Accreditation Body Under FDA’s Accredited Third Party Certification Program Keller and Heckman LLP
Jun
24
2022
Senate Committee Holds Hearing on Implementation of TSCA Amendments Bergeson & Campbell, P.C.
Jun
24
2022
IRS Issues FAQs on Superfund Excise Tax on Certain Chemical Substances Bergeson & Campbell, P.C.
Jun
24
2022
Cattle Industry Urges Health Canada to Reconsider Front-of-Package Proposed Rule Keller and Heckman LLP
Jun
24
2022
Mid-Year Regulatory Update 2022: Pharmaceuticals in India Nishith Desai Associates
Jun
23
2022
U.S. Government Files Amicus Brief in Prop 12 Case Keller and Heckman LLP
Jun
23
2022
CMS Reduces COVID-19 Vaccine Mandate Surveys and Rescinds Surveyor Vaccination Requirements Epstein Becker & Green, P.C.
Jun
23
2022
Claim Construction and Jurisdictional Discovery Are More Than Skin Deep McDermott Will & Emery
Jun
23
2022
FDA Issues Untitled Letter to Althera Pharmaceuticals for Statements Relating to ROSZET® Sheppard, Mullin, Richter & Hampton LLP
Jun
23
2022
DOJ and FTC Virtual Workshop: Agencies Discuss Novel Approaches to Address Competition Issues in Pharmaceutical Mergers Mintz
Jun
22
2022
U.S. Supreme Court Refuses to Hear Medical Cannabis Workers’ Compensation Case Wilson Elser Moskowitz Edelman & Dicker LLP
Jun
22
2022
The Pendulum Swings Both Ways: State Responses to Protect Reproductive Health Data, Post-Roe Epstein Becker & Green, P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins